Get the Stockscreener App
57.48
1.08%
-0.63
Pre-market:
58.28
0.80
+1.39%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $57.48, with a volume of 65.84M.
It is down -1.08% in the last 24 hours and down -5.24% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$58.11
Open:
$58.26
24h Volume:
65.84M
Relative Volume:
4.66
Market Cap:
$117.06B
Revenue:
$48.19B
Net Income/Loss:
$7.06B
P/E Ratio:
16.62
EPS:
3.4587
Net Cash Flow:
$12.85B
1W Performance:
-2.71%
1M Performance:
-5.24%
6M Performance:
+27.68%
1Y Performance:
-4.87%
1-Day Range:
$56.91
$58.55
1-Week Range:
$56.91
$60.80
52-Week Range:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
57.48 | 117.06B | 48.19B | 7.06B | 12.85B | 3.4587 |
LLY
Lilly Eli Co
|
906.70 | 809.68B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
235.37 | 566.92B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
205.07 | 362.60B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
183.60 | 284.73B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
114.18 | 282.30B | 64.93B | 18.26B | 12.36B | 7.2751 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Bristol Myers wins FDA approval for Opdivo in first-line Hodgkin lymphoma - MSN
Bristol Myers Squibb Co. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Bristol Myers Squibb: A Defensive Dividend Stock for Volatile MarketsNews and Statistics - IndexBox
A Look At Bristol Myers Squibb (BMY) Valuation As Recent Results Shape Growth And Cost Outlook - simplywall.st
IAM Advisory LLC Takes $1.66 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
20,156 Shares in Bristol Myers Squibb Company $BMY Purchased by MFG Wealth Management Inc. - MarketBeat
CWA Asset Management Group LLC Sells 35,291 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb stock faces pressure after earnings miss and cautious FY2026 guidance amid pipe - AD HOC NEWS
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. - PharmiWeb.com
Bristol Myers (BMY): New Approvals for Opdivo Expand Treatment O - GuruFocus
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab) - WBOC TV
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Bristol Myers Squibb (BMY) Gains FDA Approval for Expanded Use o - GuruFocus
Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma - Benzinga
Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma - Benzinga
US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma - Reuters
Here is what to know beyond why Bristol Myers Squibb Company (BMY) is a trending stock - MSN
Top Stock Picks of 2026: Bristol-Myers Squibb - Schaeffer's Investment Research
CIBC Bancorp USA Inc. Makes New Investment in Bristol Myers Squibb Company $BMY - MarketBeat
BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Bristol Myers Squibb Kidney Cancer Trial Tests Valuation And Pipeline Depth - simplywall.st
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors - MarketWatch
Swiss Life Asset Management Ltd Purchases 68,565 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Wilmington Savings Fund Society FSB Has $5.24 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026 - The Joplin Globe
Bristol-Myers Squibb Co Stock (ISIN: US1101221083) Faces Mixed Signals After Q4 Earnings Miss Amid S - AD HOC NEWS
Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation - Eagle-Tribune
BMS brings 'Emily in Paris' star and cancer survivor Ashley Park aboard campaign honoring oncologists - Fierce Pharma
Merck vs. Bristol Myers: Which pharma stock is a better pick in 2026? - MSN
WBI Investments LLC Has $2.70 Million Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
US FDA approves J&J's oral psoriasis pill - Reuters
Danske Bank A S Makes New $71.59 Million Investment in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Stake Boosted by Achmea Investment Management B.V. - MarketBeat
Physician Views Preview: Can BMS' Sotyktu provide a new oral standard of care for psoriatic arthritis? - FirstWord Pharma
Bristol-Myers Squibb Advances BMS-986278 Through Key Heart Safety Study - TipRanks
Jefferies raises Bristol-Myers Squibb stock price target on trial data - Investing.com India
Jefferies raises Bristol-Myers Squibb stock price target on trial data By Investing.com - Investing.com South Africa
Can Bristol Myers Squibb’s pipeline strategy offset a major patent cliff? - Labiotech.eu
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock - Yahoo Finance
HSBC Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $60 - 富途牛牛
Bristol Myers Squibb Company $BMY Stock Position Increased by Gotham Asset Management LLC - MarketBeat
Bristol Myers Squibb Company $BMY Stock Position Decreased by Brevan Howard Capital Management LP - MarketBeat
Bank of Nova Scotia Raises Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Raymond James reiterates Market Perform on Bristol-Myers Squibb stock By Investing.com - Investing.com Canada
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Raymond James reiterates Market Perform on Bristol-Myers Squibb stock - Investing.com
PFE vs BMY: Which Large Oncology Drugmaker Is a Better Pick Now? - TradingView
Capitolis Liquid Global Markets LLC Has $9.29 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Chevy Chase Trust Holdings LLC Sells 35,963 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
BNP Paribas Decreases Stake in Bristol Myers Squibb Company $BMY - MarketBeat
The top 10 drugs losing US exclusivity in 2026 - Fierce Pharma
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):